A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia.

Trial Profile

A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 May 2014

At a glance

  • Drugs Olanzapine (Primary) ; Haloperidol decanoate
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Aug 2011 This trial is recruiting in France and has discontinued in Hungary and United Kingdom.
    • 18 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top